Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 23 October 2024
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 30 October 2024
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 November 2024
Exagamglogene autotemcel for treating sickle cell disease [ID4016]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 December 2024
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 February 2025
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 June 2025
Suspected sepsis: recognition, diagnosis and early managementStatus:In developmentProgramme:NICE guidelineExpected publication date: 13 August 2025
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avapritinib for treating advanced systemic mastocytosis ID3770Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC